A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Interventional
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care
Subject incidence of cataract event development or progression by month 12 exceeding a predefined level at any of 3 key lens locations using LOCS III score.
one year
Yes
MD
Study Director
Amgen
Czech Republic: Statni ustav pro kontrolu leciv
20080560
NCT00925600
November 2009
July 2015
Name | Location |
---|---|
Research Site | Anaheim, California |
Research Site | Boulder, Colorado |
Research Site | Danbury, Connecticut |
Research Site | Boca Raton, Florida |
Research Site | Boise, Idaho |
Research Site | Bloomington, Indiana |
Research Site | Ames, Iowa |
Research Site | Hays, Kansas |
Research Site | Baton Rouge, Louisiana |
Research Site | Baltimore, Maryland |
Research Site | Battle Kreek, Michigan |
Research Site | Alexandria, Minnesota |
Research Site | Branson, Missouri |
Research Site | Billings, Montana |
Research Site | Grand Island, Nebraska |
Research Site | Belleville, New Jersey |
Research Site | Albany, New York |
Research Site | Asheville, North Carolina |
Research Site | Akron, Ohio |
Research Site | Allentown, Pennsylvania |
Research Site | Charleston, South Carolina |
Research Site | Chattanooga, Tennessee |
Research Site | Abilene, Texas |
Research Site | Abington, Virginia |